PROCEPT BioRobotics Corporation

procept-biorobotics.com

What Do They Do?

Sells image-guided robotic systems and single-use handpieces for minimally invasive surgery treating benign prostate enlargement, primarily to hospitals and urologists.

How Do They Make Money?

Hospitals and other buyers pay for robotic systems, single-use handpieces and other disposables; service agreements are billed annually and cover service over time.

FY2025 revenue

Who Are Their Customers?

In the United States, hospitals are the main buyers, with some sales to distribution partners, ambulatory surgery centers and leasing companies. Sales are primarily direct; outside the United States, the company also uses distribution partners.

Do Revenues Turn Into Profits?

No. It lost $95.6M in FY2025.

Operating income, FY2025

−34% of revenue

▲ +7% (Loss) vs FY2024 (−$96.6M, −43%)

Net income, FY2025

−31% of revenue

▲ +5% (Loss) vs FY2024 (−$91.4M, −41%)

Free cash flow, FY2025

−19% of revenue

▼ −44% (Loss) vs FY2024 (−$103.6M, −46%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +19%; vs $79.2M in Q2 FY2025
Net income: ▲ +37% (Loss); vs −$19.6M in Q2 FY2025

Aug 4, 2026 Reiterated 2026 revenue guidance The company kept its full-year revenue outlook at $390 million to $410 million.

Growing. Revenue grew 8.9x in 4 years, from $34.5M in FY2021 to $308.1M in FY2025, about 73% a year.

Who Do They Compete With?

Competes with Boston Scientific and Teleflex

Comments